Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 1
Submit an article Journal homepage
663
Views
61
CrossRef citations to date
0
Altmetric
SPECIAL FOCUS: Alzheimer's Disease Therapy - Drug Profile

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

William James DeardorffCorrespondence[email protected]
,
Ahmad ShobassySt. Louis University School of Medicine, 1438 South Grand St Louis, MO 63104, USA
&
George T GrossbergSt. Louis University School of Medicine, 1438 South Grand St Louis, MO 63104, USA
Pages 7-17 | Published online: 15 Dec 2014

Citations (61)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Kirsten Antonio-Tolentino & Corey R. Hopkins. (2020) Selective α7 nicotinic receptor agonists and positive allosteric modulators for the treatment of schizophrenia – a review. Expert Opinion on Investigational Drugs 29:6, pages 603-610.
Read now
Diane Stephenson. (2015) Alzheimer’s disease: current and future therapy. Expert Review of Neurotherapeutics 15:1, pages 1-2.
Read now

Articles from other publishers (59)

Zsolt Kristóf Bali, Lili Veronika Nagy, Nóra Bruszt, Kornélia Bodó, Péter Engelmann, Zsófia Hernádi, Kitti Göntér, Sai Ambika Tadepalli & István Hernádi. (2023) Increased brain cytokine level associated impairment of vigilance and memory in aged rats can be alleviated by alpha7 nicotinic acetylcholine receptor agonist treatment. GeroScience.
Crossref
Yuzhen Niu & Ping Lin. (2023) Advances of computer-aided drug design (CADD) in the development of anti-Azheimer’s-disease drugs. Drug Discovery Today 28:8, pages 103665.
Crossref
Lindsay H. Burns, Zhe Pei & Hoau‐Yan Wang. (2023) Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development. Drug Development Research.
Crossref
Michelle M. Sonsalla & Dudley W. Lamming. (2023) Geroprotective interventions in the 3xTg mouse model of Alzheimer’s disease. GeroScience 45:3, pages 1343-1381.
Crossref
Weiwei Yao, Huihui Yang & Jinfei Yang. (2022) Small-molecule drugs development for Alzheimer's disease. Frontiers in Aging Neuroscience 14.
Crossref
Natália Chermont dos Santos Moreira, Jéssica Ellen Barbosa de Freitas Lima, Marcelo Fiori Marchiori, Ivone Carvalho & Elza Tiemi Sakamoto-Hojo. (2022) Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives. Journal of Alzheimer's Disease Reports 6:1, pages 177-193.
Crossref
Ivan Emmanuel Ramos-Martínez, María Carmen Rodríguez, Marco Cerbón, Juan Carlos Ramos-Martínez & Edgar Gustavo Ramos-Martínez. (2021) Role of the Cholinergic Anti-Inflammatory Reflex in Central Nervous System Diseases. International Journal of Molecular Sciences 22:24, pages 13427.
Crossref
Agnieszka Potasiewicz, Agata Faron-Gorecka, Piotr Popik & Agnieszka Nikiforuk. (2021) Repeated treatment with alpha 7 nicotinic acetylcholine receptor ligands enhances cognitive processes and stimulates Erk1/2 and Arc genes in rats. Behavioural Brain Research 409, pages 113338.
Crossref
Teeba Athar, K. Al Balushi & Shah Alam Khan. (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease. Molecular Biology Reports 48:7, pages 5629-5645.
Crossref
Elisa Navarro, Diana M. Norden, Paige J. Trojanowski, Jonathan P. Godbout & Manuela G. López. (2021) Central Activation of Alpha7 Nicotinic Signaling Attenuates LPS-Induced Neuroinflammation and Sickness Behavior in Adult but Not in Aged Animals. Molecules 26:8, pages 2107.
Crossref
Marc R. Plagenhoef, Patrick M. Callahan, Wayne D. Beck, David T. Blake & Alvin V. TerryJr.Jr.. (2021) Aged rhesus monkeys: Cognitive performance categorizations and preclinical drug testing. Neuropharmacology 187, pages 108489.
Crossref
Marta Ximenis, José Mulet, Salvador Sala, Francisco Sala, Manuel Criado, Rosario González-Muñiz & María Jesús Pérez de Vega. (2021) Natural Polyhydroxy Flavonoids, Curcuminoids, and Synthetic Curcumin Analogs as α7 nAChRs Positive Allosteric Modulators. International Journal of Molecular Sciences 22:2, pages 973.
Crossref
Mahip K. Verma, Rajan N. Goel, Anand M. Bokare, Manoj P. Dandekar, Sarita Koul, Sagar Desai, Santoshkumar Tota, Nilendra Singh, Prashant B. Nigade, Vinod B. Patil, Dipak Modi, Maneesh Mehta, Jayasagar Gundu, Sameer S. Walunj, Navnath P. Karche, Neelima Sinha, Rajender K. Kamboj & Venkata P. Palle. (2021) LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization. European Journal of Pharmacology 891, pages 173685.
Crossref
Tingting Chen, Chengyun Cai, Lifeng Wang, Shixin Li & Ling Chen. (2020) Farnesyl Transferase Inhibitor Lonafarnib Enhances α7nAChR Expression Through Inhibiting DNA Methylation of CHRNA7 and Increases α7nAChR Membrane Trafficking. Frontiers in Pharmacology 11.
Crossref
John McDaid, Sarah Mustaly-Kalimi & Grace E. Stutzmann. (2020) Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease. Cells 9:12, pages 2655.
Crossref
Elahe Zarini-Gakiye, Javad Amini, Nima Sanadgol, Gholamhassan Vaezi & Kazem Parivar. (2020) Recent Updates in the Alzheimer’s Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials. Current Molecular Pharmacology 13:4, pages 273-294.
Crossref
Xiaohai Wang, Christopher Daley, Vanita Gakhar, Henry S. Lange, Joshua D. Vardigan, Michelle Pearson, Xiaoping Zhou, Lee Warren, Corin O. Miller, Michelle Belden, Andrew J. Harvey, Anton A. Grishin, Carolyn J. Coles, Susan M. O’Connor, Fiona Thomson, Joseph L. Duffy, Ian M. Bell & Jason M. Uslaner. (2020) Pharmacological Characterization of the Novel and Selective α 7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator BNC375 . Journal of Pharmacology and Experimental Therapeutics 373:2, pages 311-324.
Crossref
Agnieszka Potasiewicz, Martyna Krawczyk, Kinga Gzielo, Piotr Popik & Agnieszka Nikiforuk. (2020) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats. Behavioural Brain Research 385, pages 112547.
Crossref
Md. Sahab Uddin, Md. Tanvir Kabir, Philippe Jeandet, Bijo Mathew, Ghulam Md Ashraf, Asma Perveen, May N. Bin-Jumah, Shaker A. Mousa & Mohamed M. Abdel-Daim. (2020) Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. Oxidative Medicine and Cellular Longevity 2020, pages 1-19.
Crossref
Neelima Sinha, Navnath P. Karche, Mahip Kalyan Verma, Sameer S. Walunj, Prashant B. Nigade, Gourhari Jana, Sanjay P. Kurhade, Anil K. Hajare, Ajay R. Tilekar, Ganesh R. Jadhav, Baban R. Thube, Javed S. Shaikh, Sudhakar Balgude, Lairikyengbam Bikramjit Singh, Vijaya Mahimane, Shridhar K. Adurkar, Girish Hatnapure, Firoj Raje, Yogesh Bhosale, Dnyaneshwar Bhanage, Sachchidanand Sachchidanand, Ruchi Dixit, Rajesh Gupta, Anand M. Bokare, Manoj Dandekar, Ashish Bharne, Manavi Chatterjee, Sagar Desai, Sarita Koul, Dipak Modi, Maneesh Mehta, Vinod Patil, Minakshi Singh, Jayasagar Gundu, Rajan N. Goel, Chirag Shah, Sharad Sharma, Dhananjay Bakhle, Rajender Kumar Kamboj & Venkata P. Palle. (2019) Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure–Activity Relationship and Preclinical Characterization. Journal of Medicinal Chemistry 63:3, pages 944-960.
Crossref
Arunachalam Muthuraman, Muthusamy Ramesh & Thiagarajan Venkata Rathina Kumar. 2020. Principles of Neurochemistry. Principles of Neurochemistry 101 136 .
Xiaohai Wang, Ian M. Bell & Jason M. Uslaner. 2020. Behavioral Pharmacology of the Cholinergic System. Behavioral Pharmacology of the Cholinergic System 209 245 .
Hang Gao, Shuxia Wang, Bingchao Qiang, Sixuan Wang & Huabei Zhang. (2019) Radioiodinated 9-fluorenone derivatives for imaging α7-nicotinic acetylcholine receptors. MedChemComm 10:12, pages 2102-2110.
Crossref
Erika Cecon, Julie Dam, Marine Luka, Clément Gautier, Anne‐Marie Chollet, Philippe Delagrange, Laurence Danober & Ralf Jockers. (2019) Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor. British Journal of Pharmacology 176:18, pages 3475-3488.
Crossref
Steve Pedrini, Mike Morici & Ralph N. Martins. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease 391 442 .
Kai-Ge Ma & Yi-Hua Qian. (2019) Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease. Neuropeptides 73, pages 96-106.
Crossref
Anne Catrien Baakman, Ricardo Alvarez‐Jimenez, Gordon Loewen, Marieke L. Kam, Karen Broekhuizen, Dana C. Hilt & Geert Jan Groeneveld. (2019) No synergistic effect of subtherapeutic doses of donepezil and EVP‐6124 in healthy elderly subjects in a scopolamine challenge model. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5:1, pages 89-98.
Crossref
Hugo Geerts, Athan Spiros & Patrick Roberts. (2018) Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimer's Research & Therapy 10:1.
Crossref
Jiqing Cao, Jianwei Hou, Jing Ping & Dongming Cai. (2018) Advances in developing novel therapeutic strategies for Alzheimer’s disease. Molecular Neurodegeneration 13:1.
Crossref
Xicheng Yang, Jian Shen, Lulu Jiang, Wei Li, Mingcheng Yu, Guanxing Pan, Yurong Yan, Chenghan Zhang, Wanwan Jia, Li Xiao, Haihua Yu, Hao Chen, Yilin Zheng, Linqian Yu, Qiong Xie, Lu Zhou & Liming Shao. (2018) Discovery, cocrystallization and biological evaluation of novel piperidine derivatives as high affinity Ls-AChBP ligands possessing α7 nAChR activities. European Journal of Medicinal Chemistry 160, pages 37-48.
Crossref
Randi Melissa Schuster, Gladys N. Pachas, Luke Stoeckel, Corinne Cather, Mireya Nadal, David Mischoulon, David A. Schoenfeld, Haiyue Zhang, Christine Ulysse, Elisabeth B. Dodds, Sara Sobolewski, Vicenta Hudziak, Ailish Hanly, Maurizio Fava & A. Eden Evins. (2018) Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. Journal of Clinical Psychopharmacology 38:4, pages 307-316.
Crossref
Buranee Kanchanatawan, Sunee Sirivichayakul, Kiat Ruxrungtham, André F. Carvalho, Michel Geffard, George Anderson & Michael Maes. (2017) Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. Molecular Neurobiology 55:3, pages 2214-2226.
Crossref
Dina Manetti, Cristina Bellucci, Niccolò Chiaramonte, Silvia Dei, Elisabetta Teodori & Maria Novella Romanelli. (2018) Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities. Future Medicinal Chemistry 10:4, pages 433-460.
Crossref
George Anderson. (2018) Linking the biological underpinnings of depression: Role of mitochondria interactions with melatonin, inflammation, sirtuins, tryptophan catabolites, DNA repair and oxidative and nitrosative stress, with consequences for classification and cognition. Progress in Neuro-Psychopharmacology and Biological Psychiatry 80, pages 255-266.
Crossref
Michael R. Weed, Joseph Polino, Laura Signor, Mark Bookbinder, Deborah Keavy, Yulia Benitex, Daniel G. Morgan, Dalton King, John E. Macor, Robert Zaczek, Richard Olson & Linda J. Bristow. (2017) Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning. PLOS ONE 12:12, pages e0187609.
Crossref
Jos Prickaerts, Nick P. Van Goethem, Walter Gulisano, Elentina K. Argyrousi, Agostino Palmeri & Daniela Puzzo. (2017) Physiological and pathological processes of synaptic plasticity and memory in drug discovery: Do not forget the dose-response curve. European Journal of Pharmacology 817, pages 59-70.
Crossref
Taoyi Yang, Ting Xiao, Qi Sun & Kewei Wang. (2017) The current agonists and positive allosteric modulators of α 7 nAChR for CNS indications in clinical trials. Acta Pharmaceutica Sinica B 7:6, pages 611-622.
Crossref
Harald Hampel, Marsel M. Mesulam, A. Claudio Cuello, Ara S. Khachaturian, Martin R. Farlow, Peter J. Snyder, Ezio Giacobini & Zaven S. Khachaturian. (2017) WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. Alzheimer's & Dementia.
Crossref
Rick L. Pieschl, Regina Miller, Kelli M. Jones, Debra J. Post-Munson, Ping Chen, Kimberly Newberry, Yulia Benitex, Thaddeus Molski, Daniel Morgan, Ivar M. McDonald, John E. Macor, Richard E. Olson, Yukiko Asaka, Siva Digavalli, Amy Easton, James Herrington, Ryan S. Westphal, Nicholas J. Lodge, Robert Zaczek, Linda J. Bristow & Yu-Wen Li. (2017) Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents. European Journal of Pharmacology 807, pages 1-11.
Crossref
George Anderson & Michael Maes. (2017) Interactions of Tryptophan and Its Catabolites With Melatonin and the Alpha 7 Nicotinic Receptor in Central Nervous System and Psychiatric Disorders: Role of the Aryl Hydrocarbon Receptor and Direct Mitochondria Regulation. International Journal of Tryptophan Research 10, pages 117864691769173.
Crossref
Hong-Feng Zhang, Li-Bo Huang, Yan-Biao Zhong, Qi-Hui Zhou, Hui-Lin Wang, Guo-Qing Zheng & Yan Lin. (2016) An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Frontiers in Aging Neuroscience 8.
Crossref
Laura M. Gault, Robert A. Lenz, Craig W. Ritchie, Andreas Meier, Ahmed A. Othman, Qi Tang, Scott Berry, Yili Pritchett & Weining Z. Robieson. (2016) ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimer's Research & Therapy 8:1.
Crossref
Milan Stoiljkovic, Craig Kelley, Dávid Nagy, Raymond Hurst & Mihály Hajós. (2016) Activation of α7 nicotinic acetylcholine receptors facilitates long-term potentiation at the hippocampal-prefrontal cortex synapses in vivo. European Neuropsychopharmacology 26:12, pages 2018-2023.
Crossref
Milan Stoiljkovic, Craig Kelley, Dávid Nagy, Liza Leventhal & Mihály Hajós. (2016) Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations. Neuropharmacology 110, pages 102-108.
Crossref
Milan Stoiljkovic, Craig Kelley, Gábor Patrick Hajós, Dávid Nagy, Gerhard Koenig, Liza Leventhal & Mihály Hajós. (2016) Hippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice. Neurobiology of Aging 45, pages 161-168.
Crossref
Linda J. Bristow, Amy E. Easton, Yu-Wen Li, Digavalli V. Sivarao, Regina Lidge, Kelli M. Jones, Debra Post-Munson, Christopher Daly, Nicholas J. Lodge, Lizbeth Gallagher, Thaddeus Molski, Richard Pieschl, Ping Chen, Adam Hendricson, Ryan Westphal, James Cook, Christiana Iwuagwu, Daniel Morgan, Yulia Benitex, Dalton King, John E. Macor, Robert Zaczek & Richard Olson. (2016) The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia. PLOS ONE 11:7, pages e0159996.
Crossref
Hana Florian, Andreas Meier, Serge Gauthier, Stanley Lipschitz, Yunzhi Lin, Qi Tang, Ahmed A. Othman, Weining Z. Robieson & Laura M. Gault. (2016) Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Alzheimer's Disease 51:4, pages 1237-1247.
Crossref
Lieven D. Declercq, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen & Guy Bormans. (2016) Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT. Frontiers in Pharmacology 7.
Crossref
Aziz Ouach, Frederic Pin, Emilie Bertrand, Johnny Vercouillie, Zuhal Gulhan, Céline Mothes, Jean-Bernard Deloye, Denis Guilloteau, Franck Suzenet, Sylvie Chalon & Sylvain Routier. (2016) Design of α7 nicotinic acetylcholine receptor ligands using the (het)Aryl-1,2,3-triazole core: Synthesis, in vitro evaluation and SAR studies. European Journal of Medicinal Chemistry 107, pages 153-164.
Crossref
M.S. Wolfe. 2016. Developing Therapeutics for Alzheimer's Disease. Developing Therapeutics for Alzheimer's Disease 605 637 .
J.L. Cummings & K. Zhong. 2016. Developing Therapeutics for Alzheimer's Disease. Developing Therapeutics for Alzheimer's Disease 459 475 .
Ralph Aquila & Leslie Citrome. (2015) Cognitive impairment in schizophrenia: the great unmet need. CNS Spectrums 20:S1, pages 32-40.
Crossref
Alvin V. Terry Jr.Patrick M. Callahan & Caterina M. Hernandez. (2015) Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. Biochemical Pharmacology 97:4, pages 388-398.
Crossref
Fani Koukouli & Uwe Maskos. (2015) The multiple roles of the α7 nicotinic acetylcholine receptor in modulating glutamatergic systems in the normal and diseased nervous system. Biochemical Pharmacology 97:4, pages 378-387.
Crossref
Milan Stoiljkovic, Liza Leventhal, Angela Chen, Ting Chen, Rachelle Driscoll, Dorothy Flood, Hilliary Hodgdon, Raymond Hurst, David Nagy, Timothy Piser, Cuyue Tang, Matthew Townsend, Zhiming Tu, Daniel Bertrand, Gerhard Koenig & Mihaly Hajós. (2015) Concentration-response relationship of the α7 nicotinic acetylcholine receptor agonist FRM-17874 across multiple in vitro and in vivo assays. Biochemical Pharmacology 97:4, pages 576-589.
Crossref
Haruhiko Sugino, Akihito Watanabe, Naoki Amada, Miho Yamamoto, Yuta Ohgi, Dusan Kostic & Raymond Sanchez. (2015) Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Clinical Therapeutics 37:8, pages 1632-1642.
Crossref
Corinne Beinat, Samuel D. Banister, Marco Herrera, Vivian Law & Michael Kassiou. (2015) The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia. CNS Drugs 29:7, pages 529-542.
Crossref
Nick P. van Goethem, Jos Prickaerts, Devin Welty, Dorothy G. Flood & Gerhard Koenig. (2015) Continuous infusion of the α7 nicotinic acetylcholine receptor agonist EVP-6124 produces no signs of tolerance at memory-enhancing doses in rats. Behavioural Pharmacology 26:4, pages 403-406.
Crossref
Laura M. Gault, Craig W. Ritchie, Weining Z. Robieson, Yili Pritchett, Ahmed A. Othman & Robert A. Lenz. (2015) A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1:1, pages 81-90.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.